Automate Your Wheel Strategy on NVO
With Tiblio's Option Bot, you can configure your own wheel strategy including NVO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NVO
- Rev/Share 70.9894
- Book/Share 38.2151
- PB 8.1562
- Debt/Equity 0.5957
- CurrentRatio 0.7761
- ROIC 0.3599
- MktCap 1385478304840.9907
- FreeCF/Share 14.1116
- PFCF 22.0839
- PE 13.3532
- Debt/Assets 0.1976
- DivYield 0.0348
- ROE 0.6695
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | NVO | Jefferies | -- | Underperform | -- | -- | Oct. 27, 2025 |
| Upgrade | NVO | HSBC Securities | Hold | Buy | -- | -- | Oct. 1, 2025 |
| Downgrade | NVO | Morgan Stanley | Equal Weight | Underweight | -- | $47 | Sept. 29, 2025 |
| Upgrade | NVO | Berenberg | Hold | Buy | -- | -- | Sept. 17, 2025 |
| Upgrade | NVO | Rothschild & Co Redburn | Neutral | Buy | -- | -- | Sept. 16, 2025 |
| Upgrade | NVO | Bernstein | Market Perform | Outperform | -- | -- | Sept. 9, 2025 |
| Upgrade | NVO | BNP Paribas Exane | Underperform | Neutral | -- | $54 | Aug. 13, 2025 |
| Downgrade | NVO | UBS | Buy | Neutral | -- | -- | Aug. 5, 2025 |
| Downgrade | NVO | HSBC Securities | Buy | Hold | -- | $57 | July 31, 2025 |
| Downgrade | NVO | Barclays | Overweight | Equal Weight | -- | -- | July 30, 2025 |
News
Novo Nordisk is now offering its anti-obesity drug for as low as $199 per month
Published: November 17, 2025 by: Invezz
Sentiment: Positive
Novo Nordisk (NYSE: NVO) has announced sweeping price cuts for its blockbuster GLP-1 drugs, Wegovy and Ozempic, offering patients access to the lowest doses for just $199/month. New cash-paying patients will be able to access its anti-obesity treatments at that price for the first two months, the pharmaceutical behemoth confirmed in a press release today.
Read More
How Novo Nordisk Just Undercut Eli Lilly And The Trump Administration
Published: November 17, 2025 by: Investors Business Daily
Sentiment: Negative
Novo Nordisk undercut Eli Lilly and the Trump administration on Monday, slashing the cash price of its Wegovy and Ozempic.
Read More
Biopharma companies have confidence in their ability to do deals: BMO's Evan Seigerman
Published: November 14, 2025 by: CNBC Television
Sentiment: Positive
Evan Seigerman, BMO Capital Markets head of health care research, joins 'Power Lunch' to discuss what's behind the recent move in health care stocks, the state of play with GLP-1s and much more.
Read More
Novo Nordisk: Long-Term Brand Dominance At A Bargain
Published: November 13, 2025 by: Seeking Alpha
Sentiment: Positive
Dominant mega-caps with low debt deserve investors' attention. In times of prosperity, waste is common—and often sets the stage for strong cash generation when the cycle turns. Novo is enacted solid counter-measures: the CVS deal, the crackdown on compounders, and aggressive cost cutting.
Read More
Novo Nordisk, Lilly deny partnership with Mangoceuticals on obesity drugs
Published: November 13, 2025 by: Reuters
Sentiment: Negative
Novo Nordisk and Eli Lilly do not have a weight-loss drug partnership with telehealth website Mangoceuticals Inc , spokespeople for both companies said, rejecting a press release issued by the company on Thursday that described arrangements with the two leading drugmakers.
Read More
'Not been pretty': Novo Nordisk faces rare shareholder rebuke over board shake-up
Published: November 13, 2025 by: Reuters
Sentiment: Negative
Novo Nordisk faces a shareholder backlash on Friday as the Danish drugmaker's minority investors prepare a protest vote against a board shake-up forced through by its dominant shareholder, the Novo Nordisk Foundation.
Read More
Novo Nordisk CEO signals new appetite for risk in obesity deals
Published: November 12, 2025 by: Reuters
Sentiment: Positive
When Novo Nordisk CEO Mike Doustdar learned in late September that Metsera had accepted a $7.3 billion rival bid from Pfizer , he was not ready to give up just yet on the company and its portfolio of experimental obesity drugs.
Read More
WeightWatchers to sell Novo Nordisk's Wegovy pill after 2026 launch
Published: November 12, 2025 by: Reuters
Sentiment: Positive
WeightWatchers' CEO said on Wednesday it plans to sell Novo Nordisk's much-anticipated Wegovy in pill form if it is launched next year in the United States, deepening its tie-up with the Danish obesity drugmaker.
Read More
Healthy Returns: Novo Nordisk boosts the case for its upcoming obesity pill with additional data
Published: November 12, 2025 by: CNBC
Sentiment: Positive
Novo Nordisk released new data to underscore its pill's safety and effectiveness, while Trump is asked whether private plans could see lower GLP-1 costs.
Read More
Can NVO's Ozempic, Wegovy Sales Improve in 2026 After a Subdued Q3?
Published: November 12, 2025 by: Zacks Investment Research
Sentiment: Neutral
Novo Nordisk eyes a 2026 comeback as it slashes jobs, cuts U.S. semaglutide prices and focuses on expanding the reach of key drugs after a weak Q3.
Read More
Virtus SGA International Growth Q3 2025 Portfolio Activity
Published: November 11, 2025 by: Seeking Alpha
Sentiment: Neutral
At the beginning of the quarter, Virtus liquidated its position in Novo Nordisk (NVO) and used the proceeds to fund a new position in Japanese retail holding company, Fast Retailing (FRCOY). We also initiated a position in the Chinese technology company, Alibaba (BABA), by trimming a number of existing holdings. Additional shares were purchased in Adyen (ADYEY), Atlassian (TEAM), and SAP (SAP) on weakness, while positions in Arm Holdings (ARM) and L'Oreal (LRLCF) among others were trimmed on strength.
Read More
GLP-1 prices are dropping: Who exactly will benefit?
Published: November 11, 2025 by: CNBC Television
Sentiment: Positive
CNBC's Bertha Coombs asks President Trump and his team at the White House's announcement on lower prices for Eli Lilly and Novo Nordisk's GLP-1 medications, if those new prices will extend to commercial plans. Half of Americans are covered by employer and private health plans, many of which don't cover GLP-1s for weight loss because of the cost.
Read More
3 Buy-And-Forget Dividend Stocks With Snowballing Payouts
Published: November 11, 2025 by: 24/7 Wall Street
Sentiment: Positive
If the headline yield today is not something you're concerned with, and you pay more attention to how fast a yield can grow, then it's worth buying dividend stocks you can forget about for decades.
Read More
Pfizer to acquire Metsera after winning bidding contest against Novo Nordisk
Published: November 10, 2025 by: Proactive Investors
Sentiment: Positive
Metsera (NASDAQ:MTSR) announced that it has entered into an amended merger agreement with Pfizer Inc (NYSE:PFE, ETR:PFE), under which Pfizer will acquire the biotech company for up to $86.25 per share, valuing it at about $10 billion. The offer consists of $65.60 per share in cash and a contingent value right (CVR) for additional payments of up to $20.65 per share based on clinical and regulatory milestones.
Read More
Will Lower GLP-1 Prices Undermine Novo Nordisk's Near-Term Outlook?
Published: November 10, 2025 by: Zacks Investment Research
Sentiment: Negative
NVO's new U.S. pricing deal for Ozempic and Wegovy expands access but adds uncertainty to its growth and profit outlook.
Read More
Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It
Published: November 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Millions more Americans could access obesity drugs after Trump's deals with Eli Lilly, Novo Nordisk
Published: November 07, 2025 by: CNBC
Sentiment: Positive
President Donald Trump struck landmark deals with Eli Lilly and Novo Nordisk that could mark a turning point in access to their costly blockbuster obesity drugs. Medicare will start covering GLP-1s for obesity for certain patients for the first time beginning in mid-2026 – a shift that some experts say will open access to millions of older adults and could spur more employers and other private insurers to follow suit.
Read More
Eli Lilly, Novo Nordisk's Historic GLP-1 Pricing Deals - What Investors Need To Know
Published: November 07, 2025 by: Seeking Alpha
Sentiment: Positive
Novo Nordisk A/S and Eli Lilly and Company have agreed to slash US prices for Ozempic, Wegovy, Mounjaro, and Zepbound, expanding Medicare/Medicaid access. NVO's stock has dropped sharply in 2025, but the new deal could boost long-term revenue by increasing drug accessibility and wiping out compounded competition. Despite price cuts, LLY's strong US manufacturing presence and blockbuster tirzepatide sales position it for continued growth and potential $1T market cap.
Read More
Trump administration reaches deal to lower prices of obesity and diabetes drugs
Published: November 06, 2025 by: Proactive Investors
Sentiment: Positive
The Trump administration has announced agreements with pharmaceutical companies Novo Nordisk (NYSE:NVO) and Eli Lilly and Co (NYSE:LLY) to reduce the cost of GLP-1 medications used to treat obesity, diabetes, and related conditions. The initiative seeks to expand access and affordability for millions of Americans, including those covered by Medicare and Medicaid.
Read More
Eli Lilly and Novo Nordisk lower GLP-1 drug costs in new deal with Trump.
Published: November 06, 2025 by: Yahoo Finance
Sentiment: Positive
About Yahoo Finance: Yahoo Finance provides free stock ticker data, up-to-date news, portfolio management resources, comprehensive market data, advanced tools, and more information to help you manage your financial life. - Get the latest news and data at finance.yahoo.com - Download the Yahoo Finance app on Apple (https://apple.co/3Rten0R) or Android (https://bit.ly/3t8UnXO) - Follow Yahoo Finance on social: X: http://twitter.com/YahooFinance Instagram: https://www.instagram.com/yahoofinance/?hl=en TikTok: https://www.tiktok.com/@yahoofinance?lang=en Facebook: https://www.facebook.com/yahoofinance/ LinkedIn: https://www.linkedin.com/company/yahoo-finance
Read More
Here's how much weight loss drugs could cost you under Trump's deals with Eli Lilly, Novo Nordisk
Published: November 06, 2025 by: CNBC
Sentiment: Positive
President Donald Trump struck landmark deals with Eli Lilly and Novo Nordisk to slash the prices of their blockbuster weight loss drugs. Under the agreements, the monthly out-of-pocket cost of popular injections and upcoming pills could range from $50 to $350, depending on the dosage and insurance coverage a patient has.
Read More
Novo Nordisk's CagriSema was associated with significant reduction in blood pressure and showed anti-inflammatory effects while reducing the proportion of patients at risk of developing heart disease over time in new analyses at ObesityWeek®
Published: November 06, 2025 by: PRNewsWire
Sentiment: Neutral
A post hoc analysis of REDEFINE 1 demonstrated a 10.9 mmHg reduction in systolic blood pressure with investigational CagriSema (2.4 mg/2.4 mg), allowing 40% of people on blood pressure medications to reduce or stop their medication1 CagriSema treatment demonstrated a nearly 70% reduction in a key inflammatory marker associated with increased cardiovascular risk2 Data showed that fewer people on CagriSema were at intermediate-to-high risk of developing atherosclerotic cardiovascular disease (ASCVD) within the next 10 years3 PLAINSBORO, N.J. and BAGSVÆRD, Denmark , Nov. 6, 2025 /PRNewswire/ -- At ObesityWeek ® (November 4-7 in Atlanta, GA), Novo Nordisk presented new post hoc …
Read More
Novo CEO says its bid for Metsera is higher
Published: November 06, 2025 by: Reuters
Sentiment: Positive
Novo Nordisk CEO Mike Doustdar said during a White House event on Thursday that the company's bid for obesity biotech Metsera is higher than the one from rival Pfizer Inc. , which has sued both Metsera and Novo over the terms of their rival deal.
Read More
Novo Nordisk expects global sales to decline by low single digits in 2026
Published: November 06, 2025 by: Reuters
Sentiment: Negative
Novo Nordisk expects global sales to decline by low-single-digit percentage in 2026 after the drugmaker unveiled a deal on Thursday to slash prices of popular GLP-1 weight‑loss drugs for U.S. government-backed insurance programs and cash payers.
Read More
Novo Nordisk Has Downgraded Its Outlook for the Fourth Time This Year. Here's What Investors Need to Know.
Published: November 06, 2025 by: The Motley Fool
Sentiment: Negative
Sluggish growth for Novo Nordisk's GLP-1 drugs caused the company to again reduce its full-year sales guidance. Novo Nordisk faces challenges from the continued compounding of GLP-1 drugs and increased competition.
Read More
Novo Nordisk announces agreement with the U.S. Administration to bring GLP-1s to more Americans at a lower cost
Published: November 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
Novo Nordisk has agreed with the U.S.
Read More
Trump announces deals with Eli Lilly, Novo Nordisk to slash weight loss drug prices, offer some Medicare coverage
Published: November 06, 2025 by: CNBC
Sentiment: Positive
President Donald Trump announced deals with Eli Lilly and Novo Nordisk to slash the prices of some of their obesity drugs, including upcoming pills, in a landmark effort to expand access to the costly blockbuster treatments. The agreements will lower prices of GLP-1 drugs on Medicare and Medicaid and offer the treatments directly to consumers at a discount on a website the Trump administration is launching in January 2026 called TrumpRx.gov.
Read More
Trump White House confirms pricing deal with weight-loss-drug giants Eli Lilly, Novo Nordisk
Published: November 06, 2025 by: Market Watch
Sentiment: Positive
President Donald Trump's administration confirmed Thursday that it has reached a deal with Eli Lilly and Novo Nordisk that aims to deliver lower prices for their popular GLP-1 drugs to certain Medicare and Medicaid beneficiaries and to users of TrumpRx.gov, the administration's new direct-to-consumer website.
Read More
What is Metsera, the target in Pfizer's and Novo Nordisk's bidding war?
Published: November 06, 2025 by: Reuters
Sentiment: Positive
Pfizer and Novo Nordisk are locked in a bidding war for biotech firm Metsera as the pharmaceutical giants seek to augment their pipeline in the booming weight-loss drug market.
Read More
Novo Nordisk: Problems Compound, But Stock Still Cheap (Rating Downgrade)
Published: November 05, 2025 by: Seeking Alpha
Sentiment: Negative
Novo Nordisk A/S is downgraded to Buy due to emerging risks in the weight loss sector and recent Q3 2025 earnings results. NVO stock's valuation remains historically low, showing signs that a lot of risks may be priced in. A potential partnership with Hims could boost NVO's revenue growth through new channels but may further impact margins.
Read More
About Novo Nordisk A/S (NVO)
- IPO Date 1981-04-30
- Website https://www.novonordisk.com
- Industry Drug Manufacturers - General
- CEO Maziar Mike Doustdar
- Employees 77406